T-cell receptor complex recognizing Hepatitis B surface antigen peptide–HLA-DP (TCR-HBsAg-HLA-DP)

The T helper cell receptor complex recognizing HBsAg peptide–HLA-DP complexes is a specialized molecular assembly on the surface of CD4+ T lymphocytes. It consists of a heterodimeric T-cell receptor (TCR) alpha and beta chain associated with the CD3 signaling complex, specifically engineered or naturally selected to recognize Hepatitis B surface antigen (HBsAg) fragments presented by the Human Leukocyte Antigen-DP (HLA-DP), a Class II Major Histocompatibility Complex (MHC) molecule (Kamatani et al., 2009, Nature Genetics). In the context of chronic Hepatitis B virus (HBV) infection, these complexes play a critical role in orchestrating the adaptive immune response by activating T helper cells, which in turn support B-cell antibody production and enhance CD8+ cytotoxic T-cell activity (Gehring et al., 2014, Cellular & Molecular Immunology). Therapeutic strategies involving this target primarily focus on TCR-engineered T-cell (TCR-T) therapies, where a patient's T cells are modified to express these specific receptors to achieve a functional cure for HBV or to treat HBV-related hepatocellular carcinoma (Tan et al., 2015, Gastroenterology). The interaction is highly specific to the HLA-DP genotype of the patient, particularly alleles like HLA-DPB1*05:01 which are prevalent in Asian populations where HBV is endemic (Li et al., 2017, Journal of Hepatology). Clinical development of these therapies requires careful monitoring for safety concerns such as cytokine release syndrome and potential liver inflammation resulting from the rapid clearance of infected cells.

Other names

HBsAg-specific T-cell receptorHLA-DP restricted T-cell receptorHBV-specific CD4+ T-cell receptorHBsAg-HLA-DP TCR complex

The TCR complex specifically binds to HBsAg peptides presented by HLA-DP molecules on the surface of infected hepatocytes or tumor cells, triggering a signaling cascade via the CD3 complex that leads to T-cell activation, secretion of antiviral cytokines (e.g., IFN-gamma), and coordination of the immune clearance of Hepatitis B virus.